Neuronetics appoints Steven Pfanstiel as CFO; reaffirms Q2 & FY2025 guidance

Neuronetics, Inc.

Pfanstiel named CFO effective July 15, replacing retiring Steve Furlong (through March 2026).
Pfanstiel previously CFO/COO of Marinus Pharmaceuticals; 20+ years medical device/pharma experience.
Inducement grant of 400,000 RSUs vesting over 3-4 years; base salary $480k, 50% target bonus.
Reaffirms Q2 and full-year 2025 guidance; targets positive cash flow in Q3 2025.
Outgoing CFO Furlong remains as Senior Advisor to CEO through end of March 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.